CPC A61K 31/655 (2013.01) [A61P 35/00 (2018.01)] | 3 Claims |
1. A method of treatment/prevention of cancer cells which are MLH1 mutant/deficient, comprising the step of providing a pharmaceutical composition comprising therapeutically effective amount of a compound having the formula(II):
and/or pharmaceutically acceptable salts and/or pharmaceutically acceptable solvates in combination with pharmaceutically acceptable diluent, carrier or excipient thereof to a subject in need thereof.
|